Kluwer Patent Blog

Olanzapin, District Court The Hague (Rechtbank Den Haag), 24 March 2010

Mark van Gardingen (Brinkhof) · Sunday, April 18th, 2010 · Landmark European Patent Cases

The District Court of The Hague holds the Dutch part of Eli Lilly's olanzapine patent and SPC invalid because the substance olanzapine has been directly and unambiguously disclosed in a prior art document. According to the Court, the person skilled in the art will immediately recognize the error and the correction for this error in the same prior art document.

The Court notes that its decision deviates from court decisions in several other jurisdictions, such as in Germany, the United Kingdom and the United States. However, the Court does not specifically motivate why it has come to a different decision.

A full summary of this case has been published on Kluwer IP Law.

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe here.

Kluwer IP Law


The **2022 Future Ready Lawyer survey** showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?

Learn how Kluwer IP Law can support you.

79% of the lawyers think that the importance of legal technology will increase for next year.

Drive change with Kluwer IP Law.

The master resource for Intellectual Property rights and registration.



2022 SURVEY REPORT
The Wolters Kluwer Future Ready Lawyer

Leading change



This entry was posted on Sunday, April 18th, 2010 at 11:38 am and is filed under Case Law, Chemical Engineering, Netherlands, Novelty, Scope of protection

You can follow any responses to this entry through the Comments (RSS) feed. Both comments and pings are currently closed.